Seven patents currently held, every record listed here
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Aug 2042. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Aug 2042
Next term end
1
Patent families
When these terms end
Each bar runs from grant to computed term end. 2023 to 2045.
US 11,780,807
Benzoselenophene, Benzothiophene, and Benzofuran Analogs and Methods of Modulating the Serotonin 5-HT2C Receptor
Aug 11, 2042
US 12,187,678
Methods of Treating Psychological Disorders Through the Administration of Serotonin 5-HT2C Receptor Modulators
no later than Aug 11, 2042
US 12,012,380
Neuroplastogens and Non-Hallucinogenic Serotonin 5-HT2A Receptor Modulators
no later than Aug 11, 2042
US 12,275,701
Neuroplastogens and Non-Hallucinogenic Serotonin 5-HT2A Receptor Modulators
no later than Aug 11, 2042
US 12,344,582
Mixed Serotonin 5-HT2A/2C Receptor Agonists and Methods for Treating Pain and Depression
Aug 11, 2042
US 12,668,574
7-Azaindole Analogs and Methods of Treating Neurological Disorders Using the Same
Aug 11, 2042
US 12,564,560
Selective Serotonin Receptor Modulators and Methods of Making and Using the Same
Apr 1, 2045
20282033203820432045
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
7 pending applications: term is not computable until grant.Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 1 of the currently held patents qualifies as notable.
Formerly held, still cited
Notable
Ends Apr 2045 · Medium confidence
Granted 2026. Too new for citation comparison; protection runs to 2045.
now held by Park City Bio, LLC
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 10, 2027The maintenance fee for Benzoselenophene, Benzothiophene, and Benzofuran Analogs and Methods of Modulating the Serotonin 5-HT2C Receptor (US 11,780,807) comes due Apr 10, 2027. Unpaid by Oct 12, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Showing 1 to 7 of 7
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,780,807 | Benzoselenophene, Benzothiophene, and Benzofuran Analogs and Methods of Modulating the Serotonin 5-HT2C Receptor In force · Medium confidence | In force | Medium confidence | |
| US 12,012,380 | Neuroplastogens and Non-Hallucinogenic Serotonin 5-HT2A Receptor Modulators In force · Low confidence | In force | Low confidence | |
| US 12,187,678 | Methods of Treating Psychological Disorders Through the Administration of Serotonin 5-HT2C Receptor Modulators In force · Low confidence | In force | Low confidence | |
| US 12,275,701 | Neuroplastogens and Non-Hallucinogenic Serotonin 5-HT2A Receptor Modulators In force · Low confidence | In force | Low confidence | |
| US 12,344,582 | Mixed Serotonin 5-HT2A/2C Receptor Agonists and Methods for Treating Pain and Depression In force · Low confidence | In force | Low confidence | |
| US 12,441,683 | 7-Methyl Indole Analogs and Dosage Forms Containing the Same In force · Medium confidence | In force | Medium confidence | |
| US 12,668,574 | 7-Azaindole Analogs and Methods of Treating Neurological Disorders Using the Same In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 7: 1 patent in force now held by others · 7 applications pending. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
3 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed
7 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.